Skip to main content
SpringerLink
Log in

Assessment of Treatment Outcomes Following Prostate Cancer Therapy

  • Chapter
  • First Online:
Prostate Cancer: A Comprehensive Perspective

  • 2949 Accesses

Abstract

In this introductory chapter, we discuss why it is important to measure outcomes of prostate cancer therapy, which outcome measures are commonly reported, and which tools have been developed to enable such reporting.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 229.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Porter GA, Skibber JM. Outcomes research in surgical oncology. Ann Surg Oncol. 2000;7(5):367–75.

    Article  PubMed  CAS  Google Scholar 

  2. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA. 1994;272:619–26.

    Article  PubMed  CAS  Google Scholar 

  3. Ellwood PM. Shattuck lecture: outcomes management: a technology of patient experience. N Engl J Med. 1988;318:1549–56.

    Article  PubMed  CAS  Google Scholar 

  4. Bianco Jr FJ. Radical prostatectomy: surgical planning, execution, and outcomes. Curr Urol Rep. 2008;9(3):231–6.

    Article  PubMed  Google Scholar 

  5. Grocott M. Monitoring surgical outcomes: how and why? Curr Anaesth Crit Care. 2010;21(3):129–36.

    Article  Google Scholar 

  6. Miller DC, Saigal CS. Quality of care indicators for prostate cancer: progress toward consensus. Urol Oncol. 2009;27(4):427–34. Review.

    Article  PubMed  Google Scholar 

  7. Billah B, Reid CM, Shardey GC, Smith JA. A preoperative risk prediction model for 30-day mortality following cardiac surgery in an Australian cohort. Eur J Cardiothorac Surg. 2010;37(5):1086–92. Epub 2010 Feb 8.

    Article  PubMed  Google Scholar 

  8. www.rand.org/pubs/monograph_reports/2005/MR1227.pdf

  9. Alibhai SM, Leach M, Tomlinson G, Krahn MD, Fleshner N, Holowaty E, Naglie G. 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst. 2005;97(20):1525–32. Erratum in: J Natl Cancer Inst. 2007 Nov 7;99(21):1648.

    Article  PubMed  Google Scholar 

  10. Chauhan S, Patel MB, Coelho R, Liss M, Rocco B, Sivaraman AK, Palmer KJ, Coughlin GD, Ferrigni RG, Castle EP, Ahlering TE, Parra-Davila E, Patel VR. Preliminary analysis of the feasibility and safety of salvage robot-assisted radical prostatectomy after radiation failure: multi-institutional perioperative and short-term functional outcomes. J Endourol. 2011;25(6):1013–9. Epub 2011 May 13.

    Article  PubMed  Google Scholar 

  11. Cathcart P, Murphy DG, Moon D, Costello AJ, Frydenberg M. Perioperative, functional and oncological outcomes after open and minimally invasive prostate cancer surgery: experience from Australasia. BJU Int. 2011;107 Suppl 3:11–9.

    Article  PubMed  Google Scholar 

  12. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.

    Article  PubMed  Google Scholar 

  13. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96.

    Article  PubMed  Google Scholar 

  14. Lebeau T, Rouprêt M, Ferhi K, Chartier-Kastler E, Richard F, Bitker MO, Vaessen C. Assessing the complications of laparoscopic robot-assisted surgery: the case of radical prostatectomy. Surg Endosc. 2011;25(2):536–42. Epub 2010 Jul 8.

    Article  PubMed  Google Scholar 

  15. Hruza M, Weiss HO, Pini G, Goezen AS, Schulze M, Teber D, Rassweiler JJ. Complications in 2200 consecutive laparoscopic radical prostatectomies: standardised evaluation and analysis of learning curves. Eur Urol. 2010;58(5):733–41. Epub 2010 Aug 20.

    Article  PubMed  Google Scholar 

  16. www.rtog.org

  17. Hanley JA. Measuring mortality reductions in cancer screening trials. Epidemiol Rev. 2011;33(1):36–45. Epub 2011 May 30.

    Article  PubMed  Google Scholar 

  18. Bratt O, Schumacher MC. Natural history of prostate cancer, chemoprevention and active surveillance. Acta Oncol. 2011;50 Suppl 1:116–9.

    Article  PubMed  Google Scholar 

  19. Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S, Spångberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlén BJ, Johansson JE, Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352(19):1977–84.

    Article  PubMed  CAS  Google Scholar 

  20. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010;116(22):5226–34.

    Article  PubMed  Google Scholar 

  21. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman Jr OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.

    Article  PubMed  Google Scholar 

  22. Buonerba C, Federico P, D’Aniello C, Rescigno P, Cavaliere C, Puglia L, Ferro M, Altieri V, Perdonà S, De Placido S, Lorenzo GD. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. Cancer Chemother Pharmacol. 2011;67(6):1455–61. Epub 2011 Mar 2.

    Article  PubMed  CAS  Google Scholar 

  23. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D’Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM, AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6):2106–31.

    Article  PubMed  Google Scholar 

  24. Jhaveri FM, Zippe CD, Klein EA, Kupelian PA. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology. 1999;54(5):884–90.

    Article  PubMed  CAS  Google Scholar 

  25. Uchio EM, Aslan M, Wells CK, Calderone J, Concato J. Impact of biochemical recurrence in prostate cancer among US veterans. J Arch Intern Med. 2010;170(15):1390–5.

    Article  Google Scholar 

  26. Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol. 2007;51(5):1175–84. Epub 2007 Jan 12.

    Article  PubMed  Google Scholar 

  27. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591–7.

    Article  PubMed  CAS  Google Scholar 

  28. Vickers A, Savage C, Bianco F, Mulhall J, Sandhu J, Guillonneau B, Cronin A, Scardino P. Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center. Eur Urol. 2011;59(3):317–22.

    Article  PubMed  Google Scholar 

  29. Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol. 1999;17(4):1155. Review.

    PubMed  CAS  Google Scholar 

  30. Roach 3rd M, Hanks G, Thames Jr H, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–74.

    Article  PubMed  Google Scholar 

  31. Blana A, Brown SC, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Pasticier G, Rebillard X, Rewcastle JC, Robertson CN, Thuroff S, Ward JF. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int. 2009;104(8):1058–62. Epub 2009 Apr 17.

    Article  PubMed  CAS  Google Scholar 

  32. Ahmed HU, Emberton M. Benchmarks for success in focal therapy of prostate cancer: cure or control? World J Urol. 2010;28(5):577–82. Epub 2010 Sep 10. Review.

    Article  PubMed  Google Scholar 

  33. Ahmed HU, Freeman A, Kirkham A, Sahu M, Scott R, Allen C, Van der Meulen J, Emberton M. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol. 2011;185(4):1246–54. Epub 2011 Feb 22.

    Article  PubMed  CAS  Google Scholar 

  34. Nilsson S, Norlén BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol. 2004;43(4):316–81.

    Article  PubMed  Google Scholar 

  35. D’Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294(4):440–7.

    Article  PubMed  Google Scholar 

  36. D’Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351(2):125–35.

    Article  PubMed  Google Scholar 

  37. Secin FP, Savage C, Abbou C, de La Taille A, Salomon L, Rassweiler J, Hruza M, Rozet F, Cathelineau X, Janetschek G, Nassar F, Turk I, Vanni AJ, Gill IS, Koenig P, Kaouk JH, Martinez Pineiro L, Pansadoro V, Emiliozzi P, Bjartell A, Jiborn T, Eden C, Richards AJ, Van Velthoven R, Stolzenburg JU, Rabenalt R, Su LM, Pavlovich CP, Levinson AW, Touijer KA, Vickers A, Guillonneau B. The learning curve for laparoscopic radical prostatectomy: an international multicenter study. J Urol. 2010;184(6):2291–6. Epub 2010 Oct 16.

    Article  PubMed  Google Scholar 

  38. Vickers A, Bianco F, Cronin A, Eastham J, Klein E, Kattan M, Scardino P. The learning curve for surgical margins after open radical prostatectomy: implications for margin status as an oncological end point. J Urol. 2010;183(4):1360–5. Epub 2010 Feb 19.

    Article  PubMed  Google Scholar 

  39. Ray ME, Bae K, Hussain MH, Hanks GE, Shipley WU, Sandler HM. Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. J Natl Cancer Inst. 2009;101(4):228–36. Epub 2009 Feb 10.

    Article  PubMed  Google Scholar 

  40. Efficace F, Bottomley A, van Andel G. Health related quality of life in prostate carcinoma patients: a systematic review of randomized controlled trials. Cancer. 2003;97(2):377–88. Review.

    Article  PubMed  Google Scholar 

  41. Henderson A, Laing RW, Langley SE. Quality of life following treatment for early prostate cancer: does low dose rate (LDR) brachytherapy offer a better outcome? A review. Eur Urol. 2004;45(2):134–41. Review.

    Article  PubMed  Google Scholar 

  42. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822–30.

    Article  PubMed  CAS  Google Scholar 

  43. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, Brook RH. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273(2):129–35.

    Article  PubMed  CAS  Google Scholar 

  44. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56(6):899–905.

    Article  PubMed  CAS  Google Scholar 

  45. Barry MJ, Fowler Jr FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549–57; discussion 1564.

    PubMed  CAS  Google Scholar 

  46. Xylinas E, Ploussard G, Durand X, de La Taille A, Gillion N, Allory Y, Vordos D, Hoznek A, Abbou CC, Salomon L. Evaluation of combined oncological and functional outcomes after radical prostatectomy: trifecta rate of achieving continence, potency and cancer control – a literature review. Urology. 2010;76(5):1194–8.

    Article  PubMed  Google Scholar 

  47. Shikanov SA, Zorn KC, Zagaja GP, Shalhav AL. Trifecta outcomes after robotic-assisted laparoscopic prostatectomy. Urology. 2009;74(3):619–23. Epub 2009 Jul 9.

    Article  PubMed  Google Scholar 

  48. Litwin MS. Editorial comment. Evaluation of combined oncological and functional outcomes after radical prostatectomy: trifecta rate of achieving continence, potency and cancer control – a literature review. Urology. 2010;76(5):1198; author reply 1198–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Queen Mary University of London, University College Hospital London and Barts Cancer Institute, Charterhouse Square, London, EC1M 6BQ, UK

    Paul Cathcart M.D., FRCS (Urol)

  2. Department of Urology, Royal Melbourne Hospital, Grattan Street, Parkville 3050, Melbourne, VIC, Australia

    Paul Cathcart M.D., FRCS (Urol)

  3. Department of Urology, Consultant Urological Surgeon, University College Hospital, London, UK

    Paul Cathcart M.D., FRCS (Urol)

  4. Australian Prostate Cancer Research Centre, Epworth Richmond Hospital, Melbourne, VIC, Australia

    Paul Cathcart M.D., FRCS (Urol)

  5. Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

    Paul Cathcart M.D., FRCS (Urol)

  6. Division of Surgery and Interventional Science, University College London and UCLH/UCL Comprehensive Biomedical Research Centre, London, UK

    Paul Cathcart M.D., FRCS (Urol) & Mark Emberton M.B.B.S., FRCS, M.D., FRCS (Urol)

  7. Division of Surgery and Interventional Science, Department of Urology, University College Hospital London, 235 Euston Road, London, NW1 2BU, UK

    Mark Emberton M.B.B.S., FRCS, M.D., FRCS (Urol)

Authors
  1. Paul Cathcart M.D., FRCS (Urol)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Emberton M.B.B.S., FRCS, M.D., FRCS (Urol)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul Cathcart M.D., FRCS (Urol) .

Editor information

Editors and Affiliations

  1. New York Presbyterian Hospital, Brady Urologic Health Center, Weill Cornell Medical Center, East 68th Street 525, New York, 10021, New York, USA

    Ashutosh Tewari

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Cathcart, P., Emberton, M. (2013). Assessment of Treatment Outcomes Following Prostate Cancer Therapy. In: Tewari, A. (eds) Prostate Cancer: A Comprehensive Perspective. Springer, London. https://doi.org/10.1007/978-1-4471-2864-9_79

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2864-9_79

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2863-2

  • Online ISBN: 978-1-4471-2864-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation